Vertex Pharma (VRTX) Tops Q1 EPS by 68c; reiterates guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $532.04 -2.58%
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.76, $0.68 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.69 billion versus the consensus estimate of $2.58 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.55-10.75 billion, versus the consensus of $10.718 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Morgan Stanley upgrades Synopsys as it turns selective on chip stocks
- Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
